Ramantamig

DRUG3 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Multiple Myeloma

Phase 2

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

RecruitingNCT06500884

Janssen Research & Development, LLCMultiple Myeloma

Start: 2024-08-26End: 2030-05-30Target: 210Updated: 2026-08-28

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

RecruitingNCT07589634

Janssen Research & Development, LLCMultiple Myeloma

Start: 2026-06-30End: 2030-11-08Target: 230Updated: 2026-08-28

Phase 3

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

Not yet recruitingNCT07665450

Janssen Research & Development, LLCMultiple Myeloma

Start: 2026-09-22End: 2035-02-02Target: 1000Updated: 2026-08-28

Related Papers

Utility and sensitivity of wett-SA53 to measure dysgeusia associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in Relapsed/Refractory multiple myeloma: Preliminary data from the talisman study

Blood2025-11-03

Prophylactic interventions for oral toxicities with the GPRC5D×CD3 bispecific antibody talquetamab in relapsed/refractory multiple myeloma: An update on the open-label, phase 2, randomized TALISMAN study.

Journal of Clinical Oncology2025-05-28